When and How Should we be Measuring Adherence to Antiretroviral Therapy in Resource-Limited Settings?

The primary goal of treatment with antiretroviral therapy (ART) is to prevent HIV-related morbidity and mortality. The effectiveness of ART has been clearly demonstrated, as have the positive relationships between adherence to ART and viral suppression, increased CD4 cell count, positive clinical outcomes, and reduced mortality. More recently it has been shown to be associated with reduced risk of transmission to uninfected partners. High levels of adherence are critical for successful treatment. Accordingly, for ART programs to achieve their population level goals, individual adherence must be monitored accurately and frequently and prompt action must be taken when poor adherence is identified.

While the issue of adherence has been extensively studied, as the ART adherence research agenda matures, several issues around ART adherence remain critically important for further investigation including: (i) how to accurately measure adherence, (ii) how often to measure adherence in order to improve treatment outcomes, (iii) what modifiable factors are predictive of poor adherence and are targets for intervention, and (iv) what interventions will be most effective at improving treatment adherence? Each of these questions requires careful consideration as we move into the next phase of the ART roll-out where sustaining gains already made will be just as important as expanding access.

For HIV treatment, a high level of adherence equates to taking at least 80%, and possibly as high as 95%, of the correct medication, in the correct quantities, at the correct time. While reasonably easy to define, adherence to therapy is notoriously difficult to measure accurately and to date, there has been no clear consensus on the ideal way to measure it in resource-limited settings. In order to act as quickly as possible for patients with poor adherence, clinicians working with patients taking ART could benefit greatly from a simple, inexpensive, reliable method for detecting the prevalence of poor adherence. Such a measure would ideally be low cost, brief and non-intrusive so that it could be used many times over the course of treatment. It should be reliable and acceptable to respondents while also being sensitive enough to measure change. It would also be beneficial to establish the causes of non-adherence so that adherence services could be tailored to support specific patient needs. Several approaches to monitoring adherence, including self-report, pill counts and lab monitoring are currently in use and meet each of these criteria to varying degrees, but none meets them all.

1 Health Economics And Epidemiology Research Office, Department Of Internal Medicine, School Of Clinical Medicine, University Of The Witwatersrand, Johannesburg
2 Centre For Global Health & Development, Boston University, Boston, MA, USA
3 Department Of Epidemiology, Boston University, Boston, MA, USA
Self-report is the most commonly used method for measuring adherence in routine clinic settings. It has been shown to be reasonably well associated with viral suppression.\textsuperscript{15,16} Self-report data is easy to collect, inexpensive and flexible (questionnaires suit different language abilities) and can distinguish between non-adherence that is intentional (where the patient chooses not to take medicine, for example when they start to feel better or if it makes them feel worse) and unintentional (when the patient forgets about taking their medicine)\textsuperscript{17}. This last point is important as non-adherence can be the result of several different underlying causes, each of which requires different interventions.\textsuperscript{7,14} Despite its usefulness, self-report data tends to over-estimate adherence,\textsuperscript{18-20} and typically only reflects short-term adherence. Future efforts around self-report must improve the sensitivity and specificity of the approach and address whether questionnaires to assess adherence remain valid when translated and modified for different populations (i.e. different ages, sexes, socioeconomic and educational backgrounds) and countries.

The visual-analogue scale, Likert item (rating scale), pills identification test (PIT) and medication possession ratio, briefly described below in Table 1, provide estimates of ART adherence which correlate reasonably well with HIV viral suppression.\textsuperscript{21} These simple adherence measures are inexpensive and easy to administer. However, they require validation and adjustment prior to implementation in the routine clinical setting. On their own, surrogate non-computerized methods such as pill-counts or Simplified Medication Adherence Questionnaires (SMAQ) all have strengths, but they also have drawbacks and limitations (Table 1). The same is true of computerized methods such as computer-assisted self-administered interviews\textsuperscript{22}, electronic pill monitoring (micro-electronic monitoring), appointment keeping/missed visits, medication possession ratio, prescription refill days or dispensing records. Advanced technology, high cost and logistical requirements have precluded the wider application of some of these methods in sub-Saharan Africa.\textsuperscript{23} An effective adherence program for resource-limited settings may, therefore, require the combination or "triangulation" of a number of inexpensive surrogate and non-surrogate markers.\textsuperscript{14} These, inexpensive and easy to administer markers may be incorporated into electronic patient management systems to flag patients at risk for virological failure due to poor adherence. However, rigorous evaluation of these methods under routine clinical settings has yet to be conducted.

Laboratory markers provide another approach to assessing treatment adherence. Viral load is perhaps the best and most reliable indicator of poor adherence (through detection of circulating virus and treatment failure) but is expensive and not easily accessible or available in many resource-limited settings.\textsuperscript{24} As viral load is rarely accessible in resource-limited settings there is a need to identify affordable and accessible laboratory markers that correlate well with adherence, preferably one like CD4 count which is used as part of routine care.\textsuperscript{25} Although a rise in CD4 cell count on ART is more evident in patients with >95\% adherence, it has been shown to be a poor predictor of treatment failure.\textsuperscript{26} Other markers of adherence, including mean cell volume for patients on zidovudine or stavudine, serum lactate for patients on stavudine and serum lipid levels for patients on protease inhibitors have been investigated to measure adherence in the routine clinical setting.\textsuperscript{27-30} While each has shown promise, many of the markers that might be used to monitor adherence are not routinely collected. In addition, questions still remain about the cost, accessibility and reliability of these methods in resource-limited settings.

It remains to be seen whether any low cost laboratory based monitoring strategy will be effective in routine care. It will likely be necessary to develop new low cost laboratory-based monitoring tools to measure adherence affordably, accurately and reliably in the routine clinic setting.

After sorting out how to measure adherence, the next important question is how often to assess it. Much of the data on the usefulness of adherence measures come from research studies that have measured adherence monthly\textsuperscript{30}. The World Health Organization (WHO) recommends continued adherence monitoring after ART has started but does not recommend one specific method or interval\textsuperscript{31}. Nevertheless, how often adherence is measured may be of critical importance in preserving the effectiveness of first-line ART since

(Continued on page 26)
| Method                          | Description                                                                 | Advantages                                                                 | Disadvantages                                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Self-report                    | Patient recall – either count based or estimation recall over a recent period of time (i.e. patient’s assessment of pills taken in the last week out of those expected to have been taken). The recall periods could be 4 days, 1 week or 1 month | Long-standing, most common method. Simple and efficient. Short recall period of 4 days correlates with adherence rates obtained from other measures of adherence such as viral load monitoring. Easy to implement and uses existing resources | Recall-bias, time-consuming and subject to errors (over-estimation)                                                                          |
| Simplified Medication Adherence Questionnaire (SMAQ) | Widely used tool for self-reporting. Based on Morisky scale questions are asked pertaining to perceptions and practices around medication adherence | Patients are asked to identify adherence difficulties or reasons for missing a dose (i.e. When you feel better, do you stop taking your medication?). | Recall-bias, time-consuming and subject to errors (over-estimation)                                                                          |
| Visual-analog scale            | A point on a line that shows a patient’s best guess about how much (from 0 – 100%) of each drug they have taken in the past 3 or 4 weeks. | Simple to administer. Equivalent to a 3-day verbal self-report. Less time-consuming than pill-counts | Difficult to assess the validity of the questions answered. Subject to the same errors and dishonesty found with self-reporting |
| Pill counts                    | Counting the remaining doses of medication and assuming that remaining pills in excess of what is expected represent missed doses. Some studies have used announced pill counts. | Simple, cheap and objective in measuring adherence | Time consuming and prone to error. Pill dumping or pill sharing prior to clinical visit may lead to over-estimation of adherence. Does not tell you if patient took the medication, at the correct time with the appropriate dietary requirements |
| Pill identification test (PIT) | The PIT asks patients to examine a board displaying several pills for each antiretroviral drug and to identify which they have been taking. | Correct scores on the PIT have been shown to be associated with treatment adherence | May overestimate the impact of overestimate the impact of socioeconomic factors (i.e. poor literacy on adherence) |
| Likert item (rating scale)     | Participants are asked to report how closely they followed their specific schedule over the last 4 days using a 5-point scale, ranging from 1 (never) to 5 (all the time) | Simple to administer. Less time-consuming than pill-counts | Subject to the same errors and dishonesty found with self-reporting |
| Prescription-refill days or dispensing records | Provide the dates on which antiretroviral medications are dispensed. If refills are not obtained on time, it is assumed that the patient is not taking their medication between refills or is missing doses | Analyzing dispensing records for drug distribution allows for a formal, less intrusive way of flagging non-adherence | Does not tell you if patient took the medication, at the correct time with the appropriate dietary requirements |

Table 1. Measures of adherence (*non-surrogate markers of adherence) (Continued on page 27

studies from developed
countries have linked duration of treatment failure to frequency and complexity of mutation profiles. Recent data suggest that patients should be switched within 8 weeks of virologic failure to ensure sustained virological suppression and better clinical outcomes.

Data from several studies shows that possibly as much as 30%–40% of subjects who experience virological failure on a first-line regimen have no HIV drug resistance mutations present, while studies have found similar results for patients failing second-line ART. These patients, and possibly others, could benefit from adherence interventions if poor adherence was identified earlier. Such a strategy could be effective as two South African studies showed that 40-50% of patients with at least 1 viral load above 1000 copies/ml after ART initiation resuppressed their viral load after adherence counselling. Early identification of poor adherence may not only result in better treatment outcomes, but could also conserve and maximize ART regimens in settings where therapeutic options are limited. Further research is needed to determine whether more frequent measurement of adherence in routine settings could preserve first-line regimens and reduce the need for expensive second-line treatment.

Finally once we identify poor adherence in a patient we must think about how to intervene. A growing research agenda is developing around this topic, including ongoing education, supportive counseling, financial rewards for good adherence and intervening on modifiable barriers to adherence prior to starting ART. Other options for intervention include patient education and collaborative planning, adherence case management, directly observed therapy, simplified treatment regimens and adherence devices. The reasons for poor adherence should dictate what approach to take and may include lack of education about the disease, stigma, non-disclosure, depression, alcohol and substance abuse, pregnancy, low literacy, lack of social support, and cultural or religious beliefs. Treatment related factors such as side effects (i.e. taking TB and ART drugs concurrently), complexity of regimen, pill fatigue and pill burden may also contribute to poor adherence. Other factors including comorbidities, WHO stage and CD4 count at ART initiation, lack of transport (money), forgetfulness, inability to get time off work and poor patient-provider relationship have also been cited as contributing to poor adherence. While the literature on strategies to address these factors is too vast to be covered in detail here, ultimately how we intervene should be tailored to the underlying reasons for the lack of adherence.

In addition to patient participation in the process, clinicians treating patients must be active participants in striving for good adherence. The scaling up of ART treatment in sub-Saharan Africa has occurred without a proportionate increase in the number of medical personnel, thereby exacerbating already low provider-patient ratios. As programs expand to include nurses and community health workers in the management of ART, it will be important to monitor the effectiveness of different provider-patient relationships on adherence. Furthermore, as programs explore the impact of test-and-treat strategies (where patients are routinely tested and all found positive start ART immediately) or where guidelines shift to earlier initiation of patients on ART at a CD4 count <500 cells/mm³, efforts will need to be focused on ensuring that adherence is not compromised.

Adherence continues to be a concern as the scale up of ART continues. At a programmatic level, adherence levels vary greatly across different social and cultural settings and from program to program with non-adherence rates ranging from 50-80%. Non-adherence has the potential to undermine the dramatic improvements in survival seen in resource-limited settings as ART becomes more widely available. Understanding biomedical, social and cultural determinants of adherence in high-risk populations is urgently needed. While of equal importance, a simple, valid and reliable method(s) for detecting the prevalence of and reason for non-adherence is essential to monitor adherence and delay the development of drug resistant viral strains in low-, middle- and high-income countries.

References
1. Wekesa A. 2007 ART adherence in resource poor settings in sub-Saharan Africa: a multidisciplinary review. 5th African Population Conference, Arusha, Tanzania 10 -15 December 2007
2. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA, 2008; 300: 51-59
3. Lewis MP, Colbert A, Elen J, Meyers M. A qualitative study of persons who are 100% adherent to antiretroviral therapy. AIDS Care 2006; 18(2):140-148
4. Myron S. Cohen, M.D., Ying Q. Chen, Ph.D., Marybeth McCauley, M.P.H., Theresa Gamble, Ph.D., Mina C. Hosseinipour, M.D., Nagalingeswaran et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. The New England Journal of Medicine 2011; 365:493-505
5. Nilsson-Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G. Baseline predictors of three

(Continued on page 28)
types of antiretroviral therapy (ART) adherence: A 2-year follow-up. AIDS Care 2006; 18(3): 246–253

6. Poppa A, Davidson D, Deutsch J, Godfrey D, Fisher M, Head S, Horne R, Sherr L. British HIV Association (BHIVA)/British Association for sexual health and HIV (NBASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy. HIV Medicine 2004; 5:S 46–60

7. Chesney M. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30: S171–S176

8. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS 2000; 14:357–366

9. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000; 133: 21–30

10. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases 2002; 34: 1115–21

11. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Therapy 2002; 7: 185–93

12. Goldman JD, Cantrell RA, Mulenga LB, Tantabatamba BC, Ried SE, Levy JW, Limbada M, Taylor A, Saag MS, Vermund SH, Stringer JSA, Chi BH. Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral Therapy. AIDS Res Hum Retroviruses 2008; 24(8): 1031–1035

13. Chesney MA et al., The Elusive Gold Standard: Future perspectives for HIV adherence assessment and intervention. JAIDS 2006; 43: 149–155

14. Garfield, S. et al., Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Medical Research Methodology 2011; 11(1): 149

15. Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schudlen J, et al. Patient and regimen characteristics associated with self-reported non-adherence to antiretroviral therapy. PLoS ONE 2007; 2(6): e552 doi:10.1371/journal.pone.0000552

16. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. JAIDS 2000; 23:386-95

17. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24: 67-74

18. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medication. J Acquir Immune Defic Syndr 2002;31 Suppl 3:S103-6

19. Liu H, Miller LG, Hays RD, Wagner G, Golin CE, Hu W, Kahn K, Haubrich R, Kaplan AH, Wenger NS. A practical method to calibrate self-reported adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43 Suppl 1:S104-12

20. Marrazzo J, Ramjee G, Nair G et al. Pre-exposure prophylaxis for HIV women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN003). 20th Conference on retroviruses and Opportunistic infections. Atlanta, GA. March 3-6 2013. Abstract 26LB

21. Hong SY, Jerger L, Jonas A, Badi A, Cohen S, Nachega JB, Parenti JJ, Tang AM, Wanke C, Terrin N, Perek D, Blom A, Trotter AB, Jordan MR. Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. PLoS One 2013; 8(2):e56307

22. Bangsbergs DR, Bronstone A, Hofmann R. A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care 2002; 14: 3-15

23. Osterberg L and Blaschke. Adherence to medication. New England Journal of Medicine 2005; 353: 445-448

24. Ajose O, Mookerjee S, Mille EJ, Boule A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Advance online edition AIDS 2012; 26: 929-938

25. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008; 5: e109

26. Bhattacharya M and Dubey AP, Adherence to antiretroviral therapy and its correlates among HIV-infected children at an HIV clinic in New Delhi. Ann Trop Paediatr 2011; 31: 331-337

27. Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003, 17: 1565-1568

28. Romanelli F, Empey K, Pomeroy C. Macrocystosis as an indicator of medication (Zidovudine) adherence in patients with HIV infection. AIDS Patient care and STDs 2002, 16: 405-411

(Continued on page 29)
29. Segeral O, Madec Y, Ban B, Ouk V, Hak CR, Le Tiec C, Nerrienet E, Goujard C, Taburet AM, Delfraissy JF, Fontanet A. Simplified assessment of antiretroviral adherence and prediction of virological efficacy in HIV-infected patients in Cambodia. AIDS Research and Treatment 2010, 2010: 142076 (doi:10.1155/2010/142076)

30. Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS One 2012; 7(5):e36737. doi: 10.1371/journal.pone.0036737

31. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva, Switzerland. 2010

32. Hatano H, Hunt P, Weidler J, Coakley E, Hoh R, Liegler T, Martin JN, Deeks SG. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006;43:1329–1336

33. Cozzi-Lepri A, Phillips AN, Ruiz L, Cloet B, Loverday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007;21:721–732

34. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ipe V, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies (PASER). Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54(11):1660-9

35. Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA. Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095. J Am Stat Assoc 2012; 107(498):542-554

36. Wallis CL, Papathanasopoulous MA, Fox M, Conradie F, Ipe P, Orrell C, Zeinecker J, Sanne I, Wood R, McIntyre J, Stevens W; CIPRA-SA project 1 study team. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther 2012; 17(2):313-20

37. Rigsby MO, Rosen MI, Beauvais JE, Cramer JA, Rainey PM, O'Malley SS, Dieckhaus KD, Rounsaville BJ. Cue-dose behavior with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000;15(12):841-7

38. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, Wood R. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12(1): 83-8

39. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwickard G, Chaisson RE, Fielding KL, Churchyard GJ, Morris L, Grant AD. Viremia, resuppression and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009; 49 (12):1928-35

40. Reda A and Biadgilign. Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa. AIDS Research and Treatment 2012; 2012: 574656 doi:10.1155/2012/574656

41. Johnstone-Robertson SP, Hargrove J, Williams BG. Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives? HIV AIDS (Auckl) 2011;3:9-17

42. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008, 31: 213-224

43. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill CJ, Cooper C. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3(11):e438

44. Nelsen A, Gupta S, Trautner B, Petersen N, Garza A, Giordano T, Naik A, Rodriguez-Barradas M. Intention to adhere to HIV treatment: a patient-centred predictor of antiretroviral adherence. HIV Med 2013; doi: 10.1111/hiv.12032. [Epub ahead of print]

45. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-Infected South African adults. JAIDS. 2006; 43(1): 78-84

46. Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, Solomon S et al. HIV treatment adherence, patient health literacy, and health care provider-patient communication: Results from the 2010 AIDS Treatment for Life International Survey. JIAPAC 2012; 11(2): 128-33

47. Levine AJ, Hinkin CH, Castellon SA, Mason KI, Lam MN, Perkins A et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav 2005; 9(3): 355-62

48. Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the Information, Motivation and Behavioural Skills model of antiretroviral therapy adherence. AIDS Care 2005; 17(6): 661 – 673

(Continued on page 30)
49. Machtinger EL and Bangsberg DR. Adherence and HIV/AIDS: Adherence to HIV antiretroviral therapy. HRSA Care Action, U.S. Department of Health and Human Services. 2006; pp.1-30